Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUSB | P08236 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.40 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.40 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 2/20 | 0.39 |
| ▸ | HTR2C | P28335 | 2/20 | 0.39 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.38 |
| ▸ | FLT3 | P36888 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 2/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | NMT1 | P30419 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26807773 | 0.91 | RIPK2 (0.43) | GUSBHTR6RIPK2ACVR1NOD2 | |
| SCHEMBL26807780 | 0.91 | LTA4H (0.47) | GUSBHTR6RIPK2ACVR1NOD2 | |
| SCHEMBL26807760 | 0.90 | LTA4H (0.48) | GUSBHTR6RIPK2ACVR1NOD2 | |
| SCHEMBL24309513 | 0.89 | LTA4H (0.41) | GUSBHTR6RIPK2ACVR1NOD2 | |
| SCHEMBL29567157 | 0.89 | LTA4H (0.41) | GUSBHTR6RIPK2ACVR1NOD2 | |
| SCHEMBL26807468 | 0.89 | GUSB (0.42) | GUSBHTR6RIPK2ACVR1NOD2 | |
| SCHEMBL26807757 | 0.88 | GUSB (0.40) | GUSBHTR6RIPK2ACVR1NOD2 | |
| SCHEMBL26807769 | 0.88 | GUSB (0.43) | GUSBHTR6HTR2CLTA4HHTR1A | |
| SCHEMBL29566968 | 0.87 | HTR6 (0.41) | GUSBHTR6RIPK2ACVR1NOD2 | |
| SCHEMBL24309746 | 0.87 | HTR6 (0.41) | GUSBHTR6RIPK2ACVR1NOD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | GUSB 2723/4885KMT2A 4613/4885HTR6 2653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.